Figure 2. The loss of HSCs after myeloid ablation can be rescued by PGE2 or PGH2 treatments.

• A
  Schematic indicating the imaging area in the tail at 72 hpf, as indicated by the black box; fluorescence imaging of the CHT in double transgenic cd45:CFP‐NTR/runx1:mcherry embryos in DMSO and after treatment with MTZ and PGH2 or PGE2_.
• B
  Quantification of runx1:mcherry‐positive cells in double transgenic cd45:CFP‐NTR/runx1:mcherry embryos in DMSO and after treatment with MTZ and PGH2 or PGE2_.
• C
  Quantification of cd45:CFP‐positive cells in double transgenic cd45:CFP‐NTR/runx1:mcherry embryos in DMSO and after treatment with MTZ and PGH2 or PGE2_.

Data information: Statistical analysis was completed using one‐way ANOVA and multiple comparison tests. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Scale bar is 200 μm (A).

Source data are available online for this figure.